Download Canadian Cancer Clinical Trials Network receives new funding

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Canadian Cancer Clinical Trials Network receives new funding, launches online
service to connect patients to clinical trials
TORONTO, ON (January 13, 2015) – Dr. Janet Dancey, Scientific Director of the Canadian
Cancer Clinical Trials Network (3CTN), today announced that 3CTN has received funding
support from the Ontario Institute for Cancer Research (OICR), the Canadian Partnership
Against Cancer (the Partnership), the Canadian Breast Cancer Foundation (CBCF) and
CancerCare Manitoba. These contributions are the first from 3CTN’s coalition of cancer
research funding organizations. 3CTN is in the process of finalizing additional funding
commitments.
The funding will be used to establish the Network’s sites at cancer centres conducting
clinical trials across Canada. Network sites will receive financial support and other resources
to be able to increase trials available to patients. Dancey also announced that 3CTN has also
launched a new online service that will assist patients and clinicians in finding cancer clinical
trials that may be of benefit.
“This funding is great news for Canada’s cancer clinical trials infrastructure, which is
essential for bringing the most promising therapies and technologies to the clinic,” says Dr.
Tom Hudson, President and Scientific Director of OICR. “Connecting patients to clinical trials
is important in moving the science forward, but also allows us to provide avenues of
treatment for those patients who have exhausted standard treatment options.”
3CTN is a pan-Canadian initiative to improve patient access to trials and the efficiency and
quality of clinical trials activities in Canada. Its aim is to provide support and coordination
for a network of teams at cancer treatment centres and hospitals and enable the sites to
increase their capacity and capability to conduct academic trials and increase access for
patients to participate in trials.
Seven Network Regional Coordinating Centres and 15 Network Cancer Centres will be
established by 3CTN with the funding. In the future 3CTN will expand to include many
Network Affiliated Cancer Centres. Currently 3CTN has 229 clinical trials in its portfolio
including 60 pediatric trials, with more to be added as they are ready to be opened for
patients. These academic trials supported by 3CTN reflect the priorities of clinicians,
researchers, patients, ministries of health and funders.
“Connecting cancer patients with clinical trials may help to improve their chances of better
treatment and outcomes, two key elements of Canada’s national cancer strategy. By
strengthening the environment for cancer clinical trials in our country, 3CTN will improve
the quality of cancer care for all Canadians,” says Ms. Shelly Jamieson, CEO of the Canadian
Partnership Against Cancer.
“With approximately 24,000 individuals diagnosed with breast cancer each year, the
investment by CBCF to 3CTN reflects our commitment to bring new breast cancer
treatments to patients sooner. Supporting the breast cancer clinical research community is
critical for ensuring that innovative Canadian research has an opportunity to improve
outcomes and the quality of life for all Canadians affected by breast cancer,” says Ms.
Sandra Palmaro, Co-CEO Canadian Breast Cancer Foundation.
The funding contribution from CancerCare Manitoba comes as the Government of Manitoba
highlighted supporting academic clinical trials as a priority in its Speech from the Throne on
November 20, with the specific goal of increasing patient participation in clinical trials.
“Ontario is thrilled that organizations from across Canada have come together to fund this
important initiative. This network will give researchers the ability to bring life-saving
innovations into cancer centres sooner and offer more patients the opportunity to join
clinical trials. Both may lead to better treatments and healthier outcomes for people in
Ontario and around the world,” says Reza Moridi, Ontario’s Minister of Research and
Innovation.
About OICR
OICR is an innovative cancer research and development institute dedicated to prevention,
early detection, diagnosis and treatment of cancer. The Institute is an independent, not-forprofit corporation, supported by the Government of Ontario. OICR’s research programs
provided support to more than 1,700 investigators, clinician scientists, research staff and
trainees located at its headquarters and in research institutes and academia across the
Province of Ontario. OICR has key research efforts underway in small molecules, biologics,
stem cells, imaging, genomics, informatics and bio-computing. For more information, please
visit the website at www.oicr.on.ca.
About the Canadian Cancer Clinical Trials Network (3CTN)
3CTN is a pan-Canadian initiative to improve the efficiency and quality of academic clinical
trials in Canada. It will provide support and coordination for a network of teams at cancer
treatment centres and hospitals. With local-regional participation, 3CTN’s business plan will
enable sites to increase their capacity and capability to conduct academic trials. OICR, NCIC
Clinical Trials Group and Network of Network (N2) together function as the 3CTN
coordinating centre. OICR will provide the central coordinating hub and secretariat for a
network with centres across Canada. For more information please visit www.3ctn.ca
-30For more information please contact:
Ontario Institute for Cancer Research
Hal Costie
Senior Communications Officer
Email: [email protected]
Telephone: 647-963-5289